H.C. Wainwright analyst Raghuram Selvaraju downgraded ObsEva to Neutral from Buy without a price target. The FDA last month identified issues with linzagolix approvability for uterine fibroids, Selvaraju tells investors in a research note. The analyst believes that the agency may require additional pivotal studies to be conducted, which could preclude approval of the drug in the U.S. “for an extended period of time and may render it commercially non-viable.”
previous post